Genmab has made changes to its Executive Committee.
Takeaway Points
- Genmab has made changes to its Executive Committee.
- Rayne Waller joins as Executive Vice President and Chief Technology Officer.
- Brad Bailey appointed as Executive Vice President and Chief Commercial Officer.
- Anthony Mancini, Executive Vice President and Chief Operating Officer, will leave Genmab to pursue other opportunities.
Genmab, announced on Friday that it has made changes to its Executive Committee. The aim is to support Genmab’s growth and evolution into a fully integrated biotech innovation powerhouse.
According to Genmab, its Executive Committee will include Rayne Waller as Executive Vice President and Chief Technology Officer and Brad Bailey as Executive Vice President and Chief Commercial Officer. Executive Vice President and Chief Operating Officer Anthony Mancini has decided to leave Genmab to pursue other opportunities.
Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab, in a comment thanked Anthony Mancini for his contributions to the company during his time and welcomed Rayne Waller and Brad Bailey to the Executive Committee.
“I am deeply grateful to Anthony Mancini for his many contributions to Genmab during his tenure, and on behalf of the Board of Directors and the Executive Committee, I wish him continued success in his future endeavors. I’m also very pleased to welcome Rayne Waller and Brad Bailey to the Executive Committee as exceptionally talented leaders with expertise in their fields. These new additions strengthen our commitment to envision a bold future for our diverse and innovative mid- to late-stage clinical programs and pipeline that can impact the lives of as many patients as possible. I am confident in their ability to energize our teams and execute towards our 2030 vision to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO®) antibody medicines,” said Jan.
Rayne and Brad will report directly to Genmab’s President and CEO, Dr. Jan van de Winkel, and be based in Copenhagen, Denmark, and Princeton, New Jersey, respectively. They will join Jan and the rest of the Executive Committee, including Chief Financial Officer Anthony Pagano, Chief Legal Officer Birgitte Stephensen, Chief Development Officer Dr. Judith Klimovsky, Chief Medical Officer Dr. Tahi Ahmadi, Chief People Officer Chris Cozic, and Chief Strategy Officer Dr. Martine van Vugt, Genmab said in a statement.
Brad joined Genmab in 2020 as the company’s first general manager in the United States. As part of this role, he led the company’s US commercialization organization, including driving the successful launches and co-commercialization partnerships for tisotumab, vedotin, and epcoritamab.
About Genmab
Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO®) antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific.
